CN104903295B - 喹诺酮衍生物 - Google Patents

喹诺酮衍生物 Download PDF

Info

Publication number: CN104903295B
Authority: CN; China
Prior art keywords: oxo; hydroxy; carboxamido; acetic acid; dihydroquinoline
Prior art date: 2012-12-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN201380067856.4A

Other languages

English (en)

Chinese (zh)

Other versions

CN104903295A (zh

Inventor

兰吉特·C·德赛

弗拉杰什·潘迪亚

潘卡杰·R·帕特尔

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Zadusi Life Sciences Co ltd

Original Assignee

Cadila Healthcare Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-24

Filing date

2013-12-23

Publication date

2017-09-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104903295(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-23 Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd

2015-09-09 Publication of CN104903295A publication Critical patent/CN104903295A/zh

2017-09-01 Application granted granted Critical

2017-09-01 Publication of CN104903295B publication Critical patent/CN104903295B/zh

Status Active legal-status Critical Current

2033-12-23 Anticipated expiration legal-status Critical

Links

0 *C(c(cccc1)c1N1OCC2=CCCCC2)=C(C(NCC(O)=O)=O)C1=* Chemical compound *C(c(cccc1)c1N1OCC2=CCCCC2)=C(C(NCC(O)=O)=O)C1=* 0.000 description 2
KNWOXOXZPACQEC-OZDSWYPASA-N C=[O]C(C(C(C=C1/C=C\C=C/[I]=C)O)C(NCC(O)=O)=O)N1OCC1CCCC1 Chemical compound C=[O]C(C(C(C=C1/C=C\C=C/[I]=C)O)C(NCC(O)=O)=O)N1OCC1CCCC1 KNWOXOXZPACQEC-OZDSWYPASA-N 0.000 description 1
YTSWNOGDRHBYAI-UHFFFAOYSA-N CCCON(c1c(C(O)=C2C(NCC(O)=O)=O)[o]cn1)C2=O Chemical compound CCCON(c1c(C(O)=C2C(NCC(O)=O)=O)[o]cn1)C2=O YTSWNOGDRHBYAI-UHFFFAOYSA-N 0.000 description 1
XQHQQWOVDYOGIZ-UHFFFAOYSA-N Cc1cc(N(C(C(C(NCCC(O)=O)=O)=C2O)=O)OC)c2[n]1C Chemical compound Cc1cc(N(C(C(C(NCCC(O)=O)=O)=C2O)=O)OC)c2[n]1C XQHQQWOVDYOGIZ-UHFFFAOYSA-N 0.000 description 1
KPGVPLLNFPVMJC-UHFFFAOYSA-N N=C(CCCC(O)=O)C(C(C(N(c1ccccc11)OCc2ncc[o]2)=O)=C1O)=O Chemical compound N=C(CCCC(O)=O)C(C(C(N(c1ccccc11)OCc2ncc[o]2)=O)=C1O)=O KPGVPLLNFPVMJC-UHFFFAOYSA-N 0.000 description 1
UXIDJYMVGQWXGK-UHFFFAOYSA-N OC(CNC(C(C(N(C(CC1)=C2C=C1C(c1ccccc1)=O)OCc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=O Chemical compound OC(CNC(C(C(N(C(CC1)=C2C=C1C(c1ccccc1)=O)OCc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=O UXIDJYMVGQWXGK-UHFFFAOYSA-N 0.000 description 1
GCUFCWPWSIWRQP-UHFFFAOYSA-N OC(CNC(C(C(N(C1=C2CCC=C1)OCCC(F)(F)F)=O)=C2O)=O)=O Chemical compound OC(CNC(C(C(N(C1=C2CCC=C1)OCCC(F)(F)F)=O)=C2O)=O)=O GCUFCWPWSIWRQP-UHFFFAOYSA-N 0.000 description 1
QMRYKRCPDKIIMZ-UHFFFAOYSA-N OC(CNC(C(C(N(c1c2cccn1)OCCc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=[U] Chemical compound OC(CNC(C(C(N(c1c2cccn1)OCCc1ccc(C(F)(F)F)cc1)=O)=C2O)=O)=[U] QMRYKRCPDKIIMZ-UHFFFAOYSA-N 0.000 description 1
CYSKLSDTCVGFQO-UHFFFAOYSA-M OC(CNC(C(C(N(c1ccccc11)[U]Cc(cc2)ccc2F)=O)=C1O)=O)=O Chemical compound OC(CNC(C(C(N(c1ccccc11)[U]Cc(cc2)ccc2F)=O)=C1O)=O)=O CYSKLSDTCVGFQO-UHFFFAOYSA-M 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Epidemiology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Quinoline Compounds (AREA)

CN201380067856.4A 2012-12-24 2013-12-23 喹诺酮衍生物 Active CN104903295B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IN3600MU2012		2012-12-24
IN3600/MUM/2012		2012-12-24
PCT/IN2013/000796 WO2014102818A1 (en)	2012-12-24	2013-12-23	Novel quinolone derivatives

Publications (2)

Publication Number	Publication Date
CN104903295A CN104903295A (zh)	2015-09-09
CN104903295B true CN104903295B (zh)	2017-09-01

Family

ID=54148255

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201380067856.4A Active CN104903295B (zh)	2012-12-24	2013-12-23	喹诺酮衍生物

Country Status (26)

Country	Link
US (1)	US9394300B2 (2)
EP (1)	EP2935221B1 (2)
JP (1)	JP6026013B2 (2)
KR (1)	KR101733901B1 (2)
CN (1)	CN104903295B (2)
AP (1)	AP2015008502A0 (2)
AR (1)	AR094300A1 (2)
AU (1)	AU2013368843B2 (2)
BR (1)	BR112015014222B1 (2)
CA (1)	CA2894636C (2)
CL (1)	CL2015001802A1 (2)
EA (1)	EA028402B1 (2)
ES (1)	ES2660288T3 (2)
IL (1)	IL239109B (2)
JO (1)	JO3781B1 (2)
MA (1)	MA38138A1 (2)
MX (1)	MX373392B (2)
MY (1)	MY175854A (2)
NZ (1)	NZ708605A (2)
PH (1)	PH12015501452B1 (2)
SG (1)	SG11201504458XA (2)
TR (1)	TR201802305T4 (2)
TW (1)	TWI598339B (2)
UA (1)	UA117122C2 (2)
WO (1)	WO2014102818A1 (2)
ZA (1)	ZA201503814B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108484598A (zh) *	2017-05-09	2018-09-04	杭州安道药业有限公司	吲哚嗪衍生物及其在医药上的应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016034108A1 (zh) *	2014-09-02	2016-03-10	广东东阳光药业有限公司	喹啉酮类化合物及其应用
WO2016045125A1 (en) *	2014-09-28	2016-03-31	Merck Sharp & Dohme Corp.	Inhibitors of hif prolyl hydroxylase
CL2015003047A1 (es) *	2015-10-15	2016-06-17	Univ Chile	Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
JOP20190024A1 (ar)	2016-08-26	2019-02-19	Gilead Sciences Inc	مركبات بيروليزين بها استبدال واستخداماتها
CN108069957B (zh) *	2016-11-09	2022-11-04	广东东阳光药业有限公司	脯氨酰羟化酶抑制剂及其用途
JP7050165B2 (ja)	2018-02-26	2022-04-07	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
WO2021181360A1 (en) *	2020-03-13	2021-09-16	Cadila Healthcare Limited	Novel salts of quinolone compounds
US20230190731A1 (en) *	2020-03-17	2023-06-22	Zydus Lifesciences Limited	Formulation comprising hif prolyl hydroxylase inhibitors
WO2021216530A1 (en)	2020-04-20	2021-10-28	Akebia Therapeutics, Inc.	Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
CN115666539A (zh) *	2020-05-29	2023-01-31	兹杜斯生命科学有限公司	银屑病和皮肤炎性疾病的治疗
EP4157220A1 (en) *	2020-06-01	2023-04-05	Zydus Lifesciences Limited	Treatment for the inflammatory bowel disease
WO2022150623A1 (en)	2021-01-08	2022-07-14	Akebia Therapeutics, Inc.	Compounds and composition for the treatment of anemia
EP4308120A4 (en)	2021-03-19	2024-11-27	Zydus Lifesciences Limited	TREATMENT OF SICKLE CELL ANEMIA
WO2022195525A1 (en) *	2021-03-19	2022-09-22	Zydus Lifesciences Limited	A quinolone compound in solid forms and processes for the preparation thereof
WO2022238745A1 (en) *	2021-05-14	2022-11-17	Zydus Lifesciences Limited	Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors
EP4347022A1 (en)	2021-05-27	2024-04-10	Keryx Biopharmaceuticals, Inc.	Pediatric formulations of ferric citrate
CN113549011B (zh) *	2021-08-10	2023-05-09	广东东阳光药业有限公司	德度司他的共晶或盐及其制备方法和用途
CN117836275A (zh) *	2021-09-20	2024-04-05	载度思生命科学有限公司	德度司他颗粒及其组合物
EP4539934A1 (en) *	2022-06-24	2025-04-23	Zydus Lifesciences Limited	Treatment for glomerular diseases
EP4565233A1 (en) *	2022-08-01	2025-06-11	Zydus Lifesciences Limited	Treatment for aplastic anemia (aa)
WO2025087207A1 (zh)	2023-10-24	2025-05-01	杭州安道药业有限公司	含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007038571A2 (en) *	2005-09-26	2007-04-05	Smithkline Beecham Corporation	Prolyl hydroxylase antagonists
WO2007070359A2 (en) *	2005-12-09	2007-06-21	Amgen Inc.	Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007103905A2 (en) *	2006-03-07	2007-09-13	Smithkline Beecham Corporation	Prolyl hydroxylase inhibitors
WO2008138060A1 (en) *	2007-05-16	2008-11-20	Cowper Norman T	System and method for maximising solids concentration of slurry pumped through a pipeline
CN101932324A (zh) *	2007-11-30	2010-12-29	葛兰素史密斯克莱有限责任公司	脯氨酰羟化酶抑制剂
CN102574805A (zh) *	2009-08-20	2012-07-11	维福（国际）股份公司	新型喹啉铁调素拮抗剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ270267A (en)	1993-12-30	1997-03-24	Hoechst Ag	3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
WO2004108681A1 (en)	2003-06-06	2004-12-16	Fibrogen, Inc.	Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8703795B2 (en) *	2005-03-02	2014-04-22	Fibrogen, Inc.	Thienopyridine compounds, and methods of use thereof
BRPI0710527B8 (pt) *	2006-04-04	2021-05-25	Fibrogen Inc	compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20090176825A1 (en) *	2006-05-16	2009-07-09	Fitch Duke M	Prolyl hydroxylase inhibitors
US20100056516A1 (en) *	2006-07-17	2010-03-04	Williams Peter D	1-hydroxy naphthyridine compounds as anti-hiv agents
ES2393326T3 (es) *	2006-12-18	2012-12-20	Amgen, Inc	Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
US8048894B2 (en) *	2007-04-18	2011-11-01	Amgen Inc.	Quinolones and azaquinolones that inhibit prolyl hydroxylase
JP2010524935A (ja) *	2007-04-18	2010-07-22	メルク・シャープ・エンド・ドーム・コーポレイション	新規１，８−ナフチリジン化合物
EP2155746A2 (en) *	2007-05-04	2010-02-24	Amgen, Inc	Diazaquinolones that inhibit prolyl hydroxylase activity
US8030346B2 (en) *	2007-05-04	2011-10-04	Amgen Inc.	Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
AU2009217541A1 (en) *	2008-02-25	2009-09-03	Merck Sharp & Dohme Corp.	Tetrahydrothieno pyridines
CA2716798A1 (en) *	2008-02-25	2009-09-03	Merck Sharp & Dohme Corp.	Tetrahydrofuropyridones
CA2714111A1 (en) *	2008-02-25	2009-09-03	Merck Sharp & Dohme Corp.	Tetrahydro-1h-pyrrolo fused pyridones
US20110098324A1 (en) *	2008-06-25	2011-04-28	Brackley Iii James A	Prolyl hydroxylase inhibitors
EP3594213A1 (en)	2009-07-17	2020-01-15	Japan Tobacco Inc.	Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
WO2012106472A1 (en)	2011-02-02	2012-08-09	Fibrogen, Inc.	Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
EP2758058B1 (en)	2011-09-23	2017-04-26	Merck Sharp & Dohme Corp.	Substituted pyrimidines
CA2863279A1 (en) *	2012-01-31	2013-08-08	Toyama Chemical Co., Ltd.	Heterocyclic compound having anti-hiv activity

2013
- 2013-12-23 JO JOP/2013/0383A patent/JO3781B1/ar active
- 2013-12-23 MX MX2015008233A patent/MX373392B/es active IP Right Grant
- 2013-12-23 WO PCT/IN2013/000796 patent/WO2014102818A1/en not_active Ceased
- 2013-12-23 AP AP2015008502A patent/AP2015008502A0/xx unknown
- 2013-12-23 KR KR1020157016080A patent/KR101733901B1/ko active Active
- 2013-12-23 NZ NZ708605A patent/NZ708605A/en unknown
- 2013-12-23 TR TR2018/02305T patent/TR201802305T4/tr unknown
- 2013-12-23 TW TW102147766A patent/TWI598339B/zh active
- 2013-12-23 CN CN201380067856.4A patent/CN104903295B/zh active Active
- 2013-12-23 ES ES13828997.0T patent/ES2660288T3/es active Active
- 2013-12-23 EA EA201591195A patent/EA028402B1/ru not_active IP Right Cessation
- 2013-12-23 CA CA2894636A patent/CA2894636C/en active Active
- 2013-12-23 MY MYPI2015001457A patent/MY175854A/en unknown
- 2013-12-23 BR BR112015014222-2A patent/BR112015014222B1/pt active IP Right Grant
- 2013-12-23 US US14/652,024 patent/US9394300B2/en active Active
- 2013-12-23 EP EP13828997.0A patent/EP2935221B1/en active Active
- 2013-12-23 UA UAA201506784A patent/UA117122C2/uk unknown
- 2013-12-23 SG SG11201504458XA patent/SG11201504458XA/en unknown
- 2013-12-23 AU AU2013368843A patent/AU2013368843B2/en active Active
- 2013-12-23 JP JP2015548889A patent/JP6026013B2/ja active Active
- 2013-12-27 AR ARP130105055A patent/AR094300A1/es active IP Right Grant
2015
- 2015-05-27 ZA ZA2015/03814A patent/ZA201503814B/en unknown
- 2015-05-29 MA MA38138A patent/MA38138A1/fr unknown
- 2015-06-01 IL IL239109A patent/IL239109B/en active IP Right Grant
- 2015-06-22 CL CL2015001802A patent/CL2015001802A1/es unknown
- 2015-06-23 PH PH12015501452A patent/PH12015501452B1/en unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007038571A2 (en) *	2005-09-26	2007-04-05	Smithkline Beecham Corporation	Prolyl hydroxylase antagonists
WO2007070359A2 (en) *	2005-12-09	2007-06-21	Amgen Inc.	Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007103905A2 (en) *	2006-03-07	2007-09-13	Smithkline Beecham Corporation	Prolyl hydroxylase inhibitors
WO2008138060A1 (en) *	2007-05-16	2008-11-20	Cowper Norman T	System and method for maximising solids concentration of slurry pumped through a pipeline
CN101932324A (zh) *	2007-11-30	2010-12-29	葛兰素史密斯克莱有限责任公司	脯氨酰羟化酶抑制剂
CN102574805A (zh) *	2009-08-20	2012-07-11	维福（国际）股份公司	新型喹啉铁调素拮抗剂

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108484598A (zh) *	2017-05-09	2018-09-04	杭州安道药业有限公司	吲哚嗪衍生物及其在医药上的应用
US11021478B2 (en)	2017-05-09	2021-06-01	Kind Pharmaceutical	Indolizine derivatives and their application in medicine
US11655249B2 (en)	2017-05-09	2023-05-23	Kind Pharmaceutical	Indolizine derivatives and their application in medicine
US11945817B2 (en)	2017-05-09	2024-04-02	Kind Pharmaceutical	Indolizine derivatives and their application in medicine
US11970495B2 (en)	2017-05-09	2024-04-30	Kind Pharmaceutical	Indolizine derivatives and their application in medicine

Also Published As

Publication number	Publication date
TR201802305T4 (tr)	2018-03-21
ZA201503814B (en)	2016-05-25
UA117122C2 (uk)	2018-06-25
CA2894636C (en)	2018-04-03
AP2015008502A0 (en)	2015-06-30
EP2935221A1 (en)	2015-10-28
JP6026013B2 (ja)	2016-11-16
WO2014102818A1 (en)	2014-07-03
MY175854A (en)	2020-07-14
AR094300A1 (es)	2015-07-22
BR112015014222A2 (pt)	2017-07-11
MX2015008233A (es)	2015-09-29
CN104903295A (zh)	2015-09-09
TW201441196A (zh)	2014-11-01
ES2660288T3 (es)	2018-03-21
EA201591195A1 (ru)	2015-10-30
JP2016503052A (ja)	2016-02-01
JO3781B1 (ar)	2021-01-31
PH12015501452B1 (en)	2018-06-06
MA38138A1 (fr)	2016-11-30
US9394300B2 (en)	2016-07-19
BR112015014222B1 (pt)	2022-12-06
CL2015001802A1 (es)	2015-10-02
SG11201504458XA (en)	2015-07-30
CA2894636A1 (en)	2014-07-03
IL239109A0 (en)	2015-07-30
HK1211022A1 (en)	2016-05-13
MX373392B (es)	2020-04-20
PH12015501452A1 (en)	2015-09-21
AU2013368843B2 (en)	2016-02-25
KR101733901B1 (ko)	2017-05-08
KR20150085535A (ko)	2015-07-23
TWI598339B (zh)	2017-09-11
US20150299193A1 (en)	2015-10-22
NZ708605A (en)	2016-07-29
AU2013368843A1 (en)	2015-06-18
EP2935221B1 (en)	2018-02-07
IL239109B (en)	2019-07-31
EA028402B1 (ru)	2017-11-30

Legal Events

Date	Code	Title	Description
2015-09-09	PB01	Publication
2015-10-07	C10	Entry into substantive examination
2015-10-07	SE01	Entry into force of request for substantive examination
2017-09-01	GR01	Patent grant
2017-09-01	GR01	Patent grant
2023-11-10	CP01	Change in the name or title of a patent holder	Address after: India, Gujarat Patentee after: Zadusi Life Sciences Co.,Ltd. Address before: India, Gujarat Patentee before: CADILA HEALTHCARE Ltd.
2023-11-10	CP01	Change in the name or title of a patent holder

Publication	Publication Date	Title
CN104903295B (zh)	2017-09-01	喹诺酮衍生物
CN111295382B (zh)	2024-02-02	作为法尼酯x受体调节剂的桥联双环化合物
EP2257169B1 (en)	2013-06-05	Tetrahydrothieno pyridines
CN105992759B (zh)	2020-10-30	1,2-萘醌的衍生物及其制备方法
JP2010524935A (ja)	2010-07-22	新規１，８−ナフチリジン化合物
WO2018233553A1 (zh)	2018-12-27	稠合双环类化合物及其在药物中的应用
JP2021533186A (ja)	2021-12-02	ブロモドメインタンパク質阻害薬としてのイミノスルホン化合物、医薬組成物及びその医薬用途
TWI701249B (zh)	2020-08-11	Ｋv１.３抑制劑及其醫學應用
CN110655503A (zh)	2020-01-07	取代的三唑类化合物、包含其的药物组合物、其制备方法及其用途
CN111630030A (zh)	2020-09-04	作为PPAR-γ调节剂的新型苯甲酰胺衍生物
TWI683808B (zh)	2020-02-01	含有胺或(硫)醯胺之lxr調節劑
TW202019907A (zh)	2020-06-01	含有雙環核心部分之新穎lxr調節劑
CN110878096A (zh)	2020-03-13	一种1,7-萘啶类衍生物及其制备方法和用途
CN111514144B (zh)	2021-10-26	具抑制细菌葡萄糖醛酸酶活性的吡唑并[4，3-c]喹啉衍生物
CN115974872A (zh)	2023-04-18	氮杂并环衍生物、其药物组合物及其用途
HK1211022B (en)	2019-01-25	Quinolone derivatives
OA17332A (en)	2016-05-25	Novel quinolone derivatives.
TW202529740A (zh)	2025-08-01	Ｐｈｄ抑制劑化合物、組成物及使用方法